Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1991 Dec 7;303(6815):1426–1431. doi: 10.1136/bmj.303.6815.1426

Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study.

C P van Schayck 1, E Dompeling 1, C L van Herwaarden 1, H Folgering 1, A L Verbeek 1, H J van der Hoogen 1, C van Weel 1
PMCID: PMC1671690  PMID: 1837744

Abstract

OBJECTIVE--To examine the effect of bronchodilator treatment given continuously versus on demand on the progression of asthma and chronic bronchitis and to compare the long term effects of a beta 2 adrenergic drug (salbutamol) and an anticholinergic drug (ipratropium bromide). DESIGN--Two year randomised controlled prospective 'crossover' study in which patients were assigned to one of two parallel treatment groups receiving continuous treatment or treatment on demand. SETTING--29 general practices in the catchment area of the University of Nijmegen. PATIENTS--223 patients aged greater than or equal to 30 with moderate airway obstruction due to asthma or chronic bronchitis, selected by their general practitioners. INTERVENTIONS--1600 micrograms salbutamol or 160 micrograms ipratropium bromide daily (113 patients) or salbutamol or ipratropium bromide only during exacerbations or periods of dyspnoea (110). No other pulmonary treatment was permitted. MAIN OUTCOME MEASURES--Decline in ventilatory function and change in bronchial responsiveness, respiratory symptoms, number of exacerbations, and quality of life. RESULTS--Among 144 patients completing the study, after correction for possible confounding factors the decline in forced expiratory volume in one second was -0.072 l/year in continuously treated patients and -0.020 l/year in those treated on demand (p less than 0.05), irrespective of the drug. The difference in the decline in patients with asthma was comparable with that in patients with chronic bronchitis (asthma: 0.092 v -0.025 l/year; chronic bronchitis: -0.082 v -0.031 l/year). Bronchial responsiveness increased slightly (0.4 doubling dose) with continuous treatment in chronic bronchitis, but exacerbations, symptoms, and quality of life were unchanged. Salbutamol and ipratropium bromide had comparable effects on all variables investigated. CONCLUSIONS--Continuous bronchodilator treatment without anti-inflammatory treatment accelerates decline in ventilatory function. Bronchodilators should be used only on demand, with additional corticosteroid treatment, if necessary.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S70–S76. [PubMed] [Google Scholar]
  2. Boman G., Bäcker U., Larsson S., Melander B., Wåhlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983 Aug;64(6):405–415. [PubMed] [Google Scholar]
  3. Burrows B., Bloom J. W., Traver G. A., Cline M. G. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med. 1987 Nov 19;317(21):1309–1314. doi: 10.1056/NEJM198711193172103. [DOI] [PubMed] [Google Scholar]
  4. Dompeling E., van Schayck C. P., Folgering H., van den Hoogen H. J., van Weel C. Accuracy, precision and linearity of the portable flow-volume meter Microspiro HI-298. Eur Respir J. 1991 May;4(5):612–615. [PubMed] [Google Scholar]
  5. Hunt S. M., McEwen J., McKenna S. P. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985 Apr;35(273):185–188. [PMC free article] [PubMed] [Google Scholar]
  6. Peto R., Speizer F. E., Cochrane A. L., Moore F., Fletcher C. M., Tinker C. M., Higgins I. T., Gray R. G., Richards S. M., Gilliland J. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis. 1983 Sep;128(3):491–500. doi: 10.1164/arrd.1983.128.3.491. [DOI] [PubMed] [Google Scholar]
  7. Postma D. S., de Vries K., Koëter G. H., Sluiter H. J. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis. 1986 Aug;134(2):276–280. doi: 10.1164/arrd.1986.134.2.276. [DOI] [PubMed] [Google Scholar]
  8. Sanjar S., Morley J. Airway hyperreactivity. Lancet. 1988 Jul 16;2(8603):160–161. doi: 10.1016/s0140-6736(88)90707-6. [DOI] [PubMed] [Google Scholar]
  9. Sears M. R., Rea H. H., Fenwick J., Gillies A. J., Holst P. E., O'Donnell T. V., Rothwell R. P. 75 deaths in asthmatics prescribed home nebulisers. Br Med J (Clin Res Ed) 1987 Feb 21;294(6570):477–480. doi: 10.1136/bmj.294.6570.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  11. Sinclair B. L., Clark D. W., Sears M. R. Use of anti-asthma drugs in New Zealand. Thorax. 1987 Sep;42(9):670–675. doi: 10.1136/thx.42.9.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Strachan D. P., Anderson H. R., Bland J. M., Peckham C. Asthma as a link between chest illness in childhood and chronic cough and phlegm in young adults. Br Med J (Clin Res Ed) 1988 Mar 26;296(6626):890–893. doi: 10.1136/bmj.296.6626.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. van Schayck C. P., Folgering H., Harbers H., Maas K. L., van Weel C. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax. 1991 May;46(5):355–359. doi: 10.1136/thx.46.5.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. van Schayck C. P., Graafsma S. J., Visch M. B., Dompeling E., van Weel C., van Herwaarden C. L. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol. 1990 Nov;86(5):793–800. doi: 10.1016/s0091-6749(05)80185-x. [DOI] [PubMed] [Google Scholar]
  15. van Schayck C. P., van Weel C., Folgering H., Verbeek A. L., van Herwaarden C. L. Treatment of patients with airflow obstruction by general practitioners and chest physicians. Scand J Prim Health Care. 1989 Oct;7(3):137–142. doi: 10.3109/02813438909087230. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES